TW201414508A - 含５－氯－ｎ－（｛（５ｓ）－２－側氧－３－［４－（３－側氧－４－嗎啉基）苯基］－１，３－□唑啶－５－基｝甲基）－２－噻吩甲醯胺之醫藥投遞型式 - Google Patents
含５－氯－ｎ－（｛（５ｓ）－２－側氧－３－［４－（３－側氧－４－嗎啉基）苯基］－１，３－□唑啶－５－基｝甲基）－２－噻吩甲醯胺之醫藥投遞型式 Download PDFInfo
- Publication number
- TW201414508A TW201414508A TW102123589A TW102123589A TW201414508A TW 201414508 A TW201414508 A TW 201414508A TW 102123589 A TW102123589 A TW 102123589A TW 102123589 A TW102123589 A TW 102123589A TW 201414508 A TW201414508 A TW 201414508A
- Authority
- TW
- Taiwan
- Prior art keywords
- active compound
- dosage form
- release
- oral administration
- pharmaceutical dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12174797 | 2012-07-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201414508A true TW201414508A (zh) | 2014-04-16 |
Family
ID=48782297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW102123589A TW201414508A (zh) | 2012-07-03 | 2013-07-02 | 含５－氯－ｎ－（｛（５ｓ）－２－側氧－３－［４－（３－側氧－４－嗎啉基）苯基］－１，３－□唑啶－５－基｝甲基）－２－噻吩甲醯胺之醫藥投遞型式 |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US20140010876A1 (ja) |
| EP (1) | EP2869814B1 (ja) |
| JP (1) | JP6166781B2 (ja) |
| KR (1) | KR20150027284A (ja) |
| CN (1) | CN104582684A (ja) |
| AP (1) | AP3756A (ja) |
| AR (1) | AR091621A1 (ja) |
| AU (1) | AU2013286068A1 (ja) |
| BR (1) | BR112015000043A2 (ja) |
| CA (1) | CA2878123A1 (ja) |
| CL (1) | CL2015000002A1 (ja) |
| CO (1) | CO7240379A2 (ja) |
| CR (1) | CR20150001A (ja) |
| CU (1) | CU20140152A7 (ja) |
| DO (1) | DOP2015000001A (ja) |
| EA (1) | EA025016B1 (ja) |
| EC (1) | ECSP14033581A (ja) |
| ES (1) | ES2574627T3 (ja) |
| GT (1) | GT201400306A (ja) |
| HK (1) | HK1209635A1 (ja) |
| IL (1) | IL236455A0 (ja) |
| IN (1) | IN2014DN11066A (ja) |
| MA (1) | MA37721B1 (ja) |
| MX (1) | MX2015000053A (ja) |
| NZ (1) | NZ703733A (ja) |
| PE (1) | PE20150189A1 (ja) |
| PH (1) | PH12014502833A1 (ja) |
| SG (1) | SG11201408420YA (ja) |
| TN (1) | TN2014000541A1 (ja) |
| TW (1) | TW201414508A (ja) |
| UY (1) | UY34856A (ja) |
| WO (1) | WO2014005934A1 (ja) |
| ZA (1) | ZA201500759B (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102008059206A1 (de) * | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
| RS62797B1 (sr) * | 2016-02-23 | 2022-02-28 | Morgandane Scientific Llc | Postupak tretmana pacijenata zajedničkom primenom rivaroksabana i verapamila |
| CN107823166A (zh) * | 2016-09-21 | 2018-03-23 | 齐鲁制药有限公司 | 一种利伐沙班片的制备方法 |
| US20210283046A1 (en) * | 2018-07-24 | 2021-09-16 | Bayer Aktiengesellschaft | Pharmaceutical dosage form which can be administered orally and has modified release |
| WO2020020789A1 (de) * | 2018-07-24 | 2020-01-30 | Bayer Aktiengesellschaft | Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung |
| US10722486B2 (en) | 2018-08-13 | 2020-07-28 | Morgandane Scientific, LLC | Method of treating patients with a factor Xa inhibitor, aspirin, and verapamil |
| JP7465157B2 (ja) * | 2020-06-15 | 2024-04-10 | 沢井製薬株式会社 | リバーロキサバン含有口腔内崩壊錠の製造方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| NZ206600A (en) | 1983-05-11 | 1987-01-23 | Alza Corp | Osmotic drug delivery device |
| US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| US5160744A (en) | 1991-06-27 | 1992-11-03 | Alza Corporation | Verapmil therapy |
| US6919373B1 (en) * | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
| DE19747261A1 (de) | 1997-10-25 | 1999-04-29 | Bayer Ag | Osmotisches Arzneimittelfreisetzungssystem |
| DK1083879T3 (da) * | 1998-06-03 | 2005-01-31 | Alza Corp | Indretninger til at tilvejebringe forlænget medikamentterapi |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| US8092831B2 (en) * | 2002-11-08 | 2012-01-10 | Andrx Pharmaceuticals, Llc | Antihistamine and decongestant system |
| CA2537413A1 (en) * | 2003-09-02 | 2005-03-10 | Imran Ahmed | Sustained release dosage forms of ziprasidone |
| DE10355461A1 (de) * | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
| DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
| RU2011104360A (ru) * | 2008-07-08 | 2012-08-20 | Рациофарм ГмбХ (DE) | Фармацевтические соединения, содержащие 5-хлор-n-({(5s)-2-оксо-3-[4-(3-оксо-4-морфолинил)-фенил]-1,3-оксазолидин-5-ил}-митил)-2-тиофенкарбоксамид |
| GB201003734D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Delayed prolonged drug delivery |
| BR112012032816A2 (pt) * | 2010-06-22 | 2016-11-08 | Twi Pharmaceuticals | composição farmacêutica de liberação controlada, e, métodos para reduzir o efeito alimentar de uma composição de liberação controlada, reduzir o período de tempo necessário para que seja alcançado um estado estável para a metformina, para aperfeiçoar a biodisponibilidade de uma forma de dosagem de liberação controlada de matriz |
-
2013
- 2013-06-11 UY UY34856A patent/UY34856A/es not_active Application Discontinuation
- 2013-06-28 IN IN11066DEN2014 patent/IN2014DN11066A/en unknown
- 2013-06-28 EP EP13735235.7A patent/EP2869814B1/de active Active
- 2013-06-28 CN CN201380035605.8A patent/CN104582684A/zh active Pending
- 2013-06-28 MX MX2015000053A patent/MX2015000053A/es unknown
- 2013-06-28 BR BR112015000043A patent/BR112015000043A2/pt active Search and Examination
- 2013-06-28 US US13/930,094 patent/US20140010876A1/en not_active Abandoned
- 2013-06-28 EA EA201590142A patent/EA025016B1/ru not_active IP Right Cessation
- 2013-06-28 ES ES13735235.7T patent/ES2574627T3/es active Active
- 2013-06-28 NZ NZ703733A patent/NZ703733A/en not_active IP Right Cessation
- 2013-06-28 SG SG11201408420YA patent/SG11201408420YA/en unknown
- 2013-06-28 CA CA2878123A patent/CA2878123A1/en not_active Abandoned
- 2013-06-28 KR KR20157002492A patent/KR20150027284A/ko not_active Application Discontinuation
- 2013-06-28 US US14/412,487 patent/US20150125527A1/en not_active Abandoned
- 2013-06-28 AU AU2013286068A patent/AU2013286068A1/en not_active Abandoned
- 2013-06-28 JP JP2015519105A patent/JP6166781B2/ja not_active Expired - Fee Related
- 2013-06-28 AR ARP130102318 patent/AR091621A1/es unknown
- 2013-06-28 AP AP2015008208A patent/AP3756A/en active
- 2013-06-28 WO PCT/EP2013/063590 patent/WO2014005934A1/de active Application Filing
- 2013-06-28 PE PE2014002579A patent/PE20150189A1/es not_active Application Discontinuation
- 2013-07-02 TW TW102123589A patent/TW201414508A/zh unknown
-
2014
- 2014-12-19 PH PH12014502833A patent/PH12014502833A1/en unknown
- 2014-12-25 IL IL236455A patent/IL236455A0/en unknown
- 2014-12-30 EC ECIEPI201433581A patent/ECSP14033581A/es unknown
- 2014-12-30 CU CU2014000152A patent/CU20140152A7/es unknown
- 2014-12-30 GT GT201400306A patent/GT201400306A/es unknown
- 2014-12-30 TN TN2014000541A patent/TN2014000541A1/fr unknown
- 2014-12-31 MA MA37721A patent/MA37721B1/fr unknown
- 2014-12-31 CO CO14287291A patent/CO7240379A2/es unknown
-
2015
- 2015-01-02 CL CL2015000002A patent/CL2015000002A1/es unknown
- 2015-01-02 DO DO2015000001A patent/DOP2015000001A/es unknown
- 2015-01-05 CR CR20150001A patent/CR20150001A/es unknown
- 2015-02-02 ZA ZA2015/00759A patent/ZA201500759B/en unknown
- 2015-10-23 HK HK15110431.9A patent/HK1209635A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI484957B (zh) | 包含硝苯地平或尼索地平及血管收縮素ii拮抗劑及／或利尿劑之醫藥劑型 | |
| EP1448235B1 (en) | Oral controlled release pharmaceutical compositions of 5,8,14-triazatetracyclo 10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene | |
| AU2005324132B2 (en) | Solid, orally applicable pharmaceutical administration forms containing rivaroxaban having modified release | |
| TW201414508A (zh) | 含５－氯－ｎ－（｛（５ｓ）－２－側氧－３－［４－（３－側氧－４－嗎啉基）苯基］－１，３－□唑啶－５－基｝甲基）－２－噻吩甲醯胺之醫藥投遞型式 | |
| JP5604304B2 (ja) | 口腔内崩壊性固形製剤 | |
| JP5366558B2 (ja) | 口腔内崩壊性固形製剤 | |
| EP2830618B1 (en) | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt | |
| JP2016034947A (ja) | Ｊａｋ３インヒビターを含む制御型経口投与製剤 | |
| JP2006528237A (ja) | バレニクリンの医薬組成物 | |
| TW201014850A (en) | Solid pharmaceutical composition | |
| TWI586353B (zh) | Pharmaceutical preparations containing calcium antagonists and angiotensin II receptor antagonists | |
| JP2019526591A (ja) | ロスバスタチン及びエゼチミブを含む医薬組成物並びにその調製方法 | |
| TWI574690B (zh) | 立即釋放４－甲基－３［［４－（３－吡啶基）－２－嘧啶基］胺基］－ｎ－［５－（４－甲基－１ｈ－咪唑－１－基）－３－（三氟甲基）苯基］苯甲醯胺調配物 | |
| JPH11147819A (ja) | 安定化された医薬製剤 | |
| WO2009027786A2 (en) | Matrix dosage forms of varenicline | |
| EP3984529A1 (en) | Timed-elution masking particles and oral pharmaceutical composition containing same | |
| JPWO2015046383A1 (ja) | 原薬含有核の製造方法、原薬含有核、医薬品組成物、及び口腔内崩壊錠 | |
| WO2022210829A1 (ja) | アビラテロン酢酸エステル含有錠剤 | |
| AU2017244269A1 (en) | Composite capsule preparation containing tadalafil and tamsulosin and having improved stability and elution rate | |
| TW201607568A (zh) | 包含１－［６－（嗎啉－４－基）嘧啶－４－基］－４－（１ｈ－１，２，３－三唑－１－基）－１ｈ－吡唑－５－醇鈉之醫藥劑型 | |
| CA2563052A1 (en) | Pharmaceutical compositions of 5,8,14-triazatetracyclo[10.3.1.02,11.0 4,9]-hexadeca-2(11)3,5,7,9-pentaene | |
| MX2008000275A (es) | Formas de dosificacion farmaceutica que comprenden una combinacion de ingrediente activo de hifedipina y/o nisoldipina y un antagonista de angiotensina ii |